CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 964 enrolled
Drug / intervention
Placebo +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03675308
NCT03675308Phase 3Active

A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

AbbVie·interventional·Posted Sep 18, 2018·Updated Aug 5, 2025

In Brief

A Phase 3 clinical trial evaluating Placebo and Risankizumab for Psoriatic Arthritis. Active but no longer recruiting, targeting 964 participants across 256 sites in 39 countries.

Detailed Summary

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Ukraine, United Kingdom, United States
Collaborators--

Timeline

Phase 3Active
20192020202120222023202420252026
First PostedSep 18, 2018
Enrollment StartMar 25, 2019
Primary CompletionOct 8, 2020
Study CompletionSep 28, 2026
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.8 years ago

Interventions

Placebobiological

Placebo for risankizumab administered by subcutaneous injection

Risankizumabbiological

Risankizumab administered by subcutaneous injection